We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-UPDATE 2-Strong sterling knocks FTSE 100 despite trade lull

Thu, 05th Sep 2019 09:29

(Reinstates dropped word 'said' in para 7)

* FTSE 100 down 0.6%, FTSE 250 up 0.2%

* Exporter stocks fall as pound surges

* CYBG tanks on mid-caps

* Online retailer Boohoo jumps after forecast upgrade

* Industrials up on upbeat forecast from European peers

By Muvija M and Indranil Sarkar

Sept 5 (Reuters) - London's FTSE 100 slipped on Thursday as
a surge in sterling pushed exporter stocks lower, missing out on
a global rally led by growing hopes of a resolution to the
U.S.-China trade dispute.

The FTSE 100 slid 0.6%, with multinationals
including spirits company Diageo, pharma giants
AstraZeneca and GlaxoSmithKline slipping about
3% as a strong pound meant the value of their U.S. earnings was
lower.

Sterling recorded its biggest two-day rise in 10 months as
no-deal Brexit worries took a break, after lawmakers voted to
prevent Prime Minister Boris Johnson from taking Britain out of
the European Union without a deal on Oct. 31.

Strength in the local currency lifted the more domestically
focussed mid-cap index by 0.2%, despite a 21% slump in
CYBG to an all-time low. The Yorkshire Bank and Virgin
Money owner said it expected to increase its provision for
legacy payment protection insurance costs.

Stocks trading without dividend entitlement on the day such
as BHP, Glencore and Micro Focus fell
between 1.2%-3%, weighing heavily on the blue-chip index. Micro
Focus is also set to be relegated from the index later this
month.

Meanwhile, indexes on Wall Street and Europe scaled a
one-month high as agreement by China and the United States to
hold high-level trade talks in October spurred hopes that the
trade dispute between the countries would be resolved.

"If one was feeling cynical, Thursday's rally could be used
to illustrate investors' refusal to learn from their past
mistakes, stung time and time again by a pair of superpowers who
never manage to deliver on their trade talk promises," said
Spreadex analyst Connor Campbell.

The FTSE 100 had suffered its only monthly fall this year in
August when trade tensions escalated between the world's largest
economies.

As investors turned to riskier assets on account of renewed
trade hopes and away from safe haven gold, precious metals miner
Fresnillo tumbled nearly 6% and was the steepest faller
on the FTSE 100.

Industrial giants BAE Systems and Rolls-Royce
helped limit the index's fall with gains of 1% each after
French engine maker Safran hiked a profit forecast and
Rafale warplanes maker Dassault Aviation affirmed a
higher net sales target.

Another prominent gainer was turnaround specialist Melrose
which jumped 9% after its first-half profit beat
estimates.

On the mid-cap bourse, specialist media services company
Future Plc surged 10% after upbeat forecast, while
payments solutions provider Network International lost
7.5% as its major shareholder Emirates NBD Bank sold stock at a
discount.

AIM-listed online fashion retailer Boohoo shot up
by 15.1% to a life high after raising its annual revenue growth
forecast and small-cap oil firm EnQuest climbed 7% after
affirming its full-year production view and cutting debt.
(Reporting by Shashwat Awasthi, Muvija M and Indranil Sarkar in
Bengaluru; Editing by Bernard Orr)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.